Type: Oral
Session: 503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences
Hematology Disease Topics & Pathways:
Research, Epidemiology, Clinical Research, Survivorship
Methods: This was a retrospective cohort study of 1931 consecutive patients who underwent a first autologous HCT for lymphoma or myeloma between 2010 and 2016 at a single center, with available pre-HCT DNA obtained from peripheral blood stem cells (99% of the overall cohort). We performed targeted exome sequencing of DNA (92 pre-defined gene panel with 1000x sequencing depth) to determine the presence of CHIP variants (variant allele frequency [VAF] ≥2%). The primary outcome was eight-year (y) cumulative incidence of non-myeloid SMN (non-dermatologic solid malignancy, melanoma, or de novo lymphoma). Cumulative incidence of non-myeloid SMNs was calculated, taking into consideration competing risk of death. Multivariable logistic regression was used to identify variables associated with risk (odds ratio [OR]) of having CHIP, and Fine–Gray multivariable regression was used to evaluate the association between CHIP and non-myeloid SMNs, adjusting for relevant sociodemographic and clinical variables and accounting for death as competing risk.
Results: Median age at HCT was 58.8y (range 18.4-78.1y); 59.1% were male; race/ethnicity: non-Hispanic White (51.5%), Hispanic (25.4%), Asian (10.9%), Black (10.8%); 53.2% had lymphoma and 46.8% had myeloma; 36.7% had Karnofsky Performance Scale (KPS) ≤80 at HCT and 47.1% had high (≥3) HCT-comorbidity index (CI). The cohort provided 8,730 person-years of follow-up. CHIP: Overall, 389 patients (20.1% of the cohort) had at least one CHIP variant and 94 (4.9%) had ≥2 variants. Among the identified CHIP variants, 78.1% had calculated VAFs 2-<10% and 21.9% had VAFs ≥10%. DNMT3A was the most frequently mutated gene (36.6%), followed by TET2 (15.2%), PPM1D (13.1%), ASXL1 (6.7%), and TP53 (6.3%). In the multivariable model, factors independently associated with odds of having CHIP were older (≥60y) age at HCT (adjusted OR [aOR]=2.8; 95%CI, 2.2-3.5) and a higher HCT-CI score (aOR=1.1; 95%CI, 1.1-1.2). Non-myeloid SMNs: In total, 115 patients developed non-myeloid SMNs after HCT. The 8-year cumulative incidence of non-myeloid SMNs was significantly higher in patients with CHIP, compared to those without CHIP (15.0% vs 7.2%, p<0.001); the incidence increased by VAF: 0-2% (7.2%), 2-<10% (14.0%), and ≥10% (19.4%), p=0.001. The presence of a TP53 CHIP mutation was associated with a particularly higher incidence of non-myeloid SMNs, compared to no CHIP (23.9% vs 7.2%, p=0.03). In the adjusted (age, sex, race/ethnicity, and KPS) multivariable model, CHIP was significantly and independently associated with risk of developing a non-myeloid SMN (adjusted hazard ratio [aHR]=1.7, 95%CI=1.1-2.3; reference: no CHIP).
Conclusions: In this well-characterized and demographically diverse cohort of patients undergoing HCT, CHIP was associated with a significant and independent risk of non-myeloid SMNs after HCT. Notably, patients with high VAF CHIP or TP53 CHIP mutations had an exceptionally elevated risk of non-myeloid SMNs. These findings may provide new insights into the pathobiology of non-myeloid SMNs after HCT, and further underscore the potential for CHIP as a novel biomarker for risk-based monitoring of subsequent cancers in HCT survivors.
Disclosures: Rhee: Pfizer: Research Funding. Goldsmith: Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees. Rosenzweig: Pfizer: Ended employment in the past 24 months, Research Funding; BMS: Ended employment in the past 24 months, Speakers Bureau; ROMTech: Current equity holder in private company; Janssen: Ended employment in the past 24 months, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Herrera: Seattle Genetics: Consultancy, Research Funding; Takeda: Consultancy; Caribou Biosciences: Consultancy; AstraZeneca: Consultancy, Research Funding; Adicet Bio: Consultancy; Pfizer: Consultancy; Genmab: Consultancy; AbbVie: Consultancy; Merck: Consultancy, Research Funding; Allogene Therapeutics: Consultancy; ADC Therapeutics: Consultancy, Research Funding; Karyopharm: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Regeneron: Consultancy; Tubulis: Consultancy; Gilead Sciences: Research Funding; KiTE Pharma: Research Funding; Roche/Genentech: Consultancy, Research Funding. Mei: Novartis: Consultancy; Synethkine: Consultancy; SeaGen: Consultancy, Speakers Bureau; ADC Therapeutics: Consultancy; AstraZeneca: Consultancy; BMS: Research Funding; Incyte: Research Funding; Beigene: Research Funding; Genentech: Research Funding. Nakamura: Omeros (ended): Consultancy; Sanofi: Consultancy; Maat Pharma: Research Funding; Pfizer: Consultancy; Helocyte: Research Funding; Ono Pharmaceutical: Consultancy; Mitarisan: Research Funding; Blue Bird (ended): Consultancy. Forman: Lixte Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Allogene: Consultancy, Membership on an entity's Board of Directors or advisory committees. Armenian: Pfizer: Research Funding.
See more of: Oral and Poster Abstracts